Critical care medicine · 2026
Impact of Molecular Adsorbent Recirculating System Therapy on Piperacillin Concentration in Critically Ill Patients: An Observational Cohort Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Monet Clément, Allegre Lucas, Kozoriz Alina, Herman Fanchon, Lakbar Ines, Prades Albert, Pensier Joris, De Jong Audrey, Molinari Nicolas, Jaber Samir
Аннотация
OBJECTIVES: To assess the impact of Molecular Adsorbent Recirculating System (MARS) therapy on total plasma piperacillin concentrations in critically ill patients with acute liver failure or acute-on-chronic liver failure.
DESIGN: Retrospective, single-center observational cohort study.
SETTING: University ICU.
PATIENTS: Consecutive adult patients treated with MARS therapy and piperacillin-tazobactam between March 2023 and June 2025.
INTERVENTIONS: MARS therapy was delivered as 8-hour sessions for up to three consecutive days. Piperacillin-tazobactam was administered by continuous infusion following a loading dose.
MEASUREMENTS AND MAIN RESULTS: Venous blood samples were collected immediately before and after each MARS session. Total piperacillin concentrations were quantified using ultrahigh-performance liquid chromatography. The primary endpoint was the relative reduction in plasma piperacillin concentration induced by MARS therapy. Thirty patients (121 piperacillin measurements across 77 sessions) were analyzed. Seventy-three percent had cirrhosis (median Model for End-Stage Liver Disease Score 31 [23-38]). The mean relative reduction in piperacillin concentration per session was 34% (± 7.9%; p < 0.05). In univariable mixed-effects analysis, MARS session (β -47.49 mg/L; p < 0.001) and creatinine clearance (β -0.37 mg/L per mL/min; p < 0.001) were associated with lower concentrations. In multivariable modeling, higher creatinine clearance was independently associated with greater intra-session piperacillin loss ( p < 0.001), whereas higher bilirubin levels were associated with reduced drug loss ( p = 0.01). Overall, 31.6% of post-session concentrations were less than 80 mg/L, and 38% of patients had at least one concentration outside the predefined target range.
CONCLUSIONS: MARS therapy was associated with a one-third reduction in total plasma piperacillin concentrations per session. These findings support systematic therapeutic drug monitoring and individualized antibiotic dose adjustment during MARS therapy.
DESIGN: Retrospective, single-center observational cohort study.
SETTING: University ICU.
PATIENTS: Consecutive adult patients treated with MARS therapy and piperacillin-tazobactam between March 2023 and June 2025.
INTERVENTIONS: MARS therapy was delivered as 8-hour sessions for up to three consecutive days. Piperacillin-tazobactam was administered by continuous infusion following a loading dose.
MEASUREMENTS AND MAIN RESULTS: Venous blood samples were collected immediately before and after each MARS session. Total piperacillin concentrations were quantified using ultrahigh-performance liquid chromatography. The primary endpoint was the relative reduction in plasma piperacillin concentration induced by MARS therapy. Thirty patients (121 piperacillin measurements across 77 sessions) were analyzed. Seventy-three percent had cirrhosis (median Model for End-Stage Liver Disease Score 31 [23-38]). The mean relative reduction in piperacillin concentration per session was 34% (± 7.9%; p < 0.05). In univariable mixed-effects analysis, MARS session (β -47.49 mg/L; p < 0.001) and creatinine clearance (β -0.37 mg/L per mL/min; p < 0.001) were associated with lower concentrations. In multivariable modeling, higher creatinine clearance was independently associated with greater intra-session piperacillin loss ( p < 0.001), whereas higher bilirubin levels were associated with reduced drug loss ( p = 0.01). Overall, 31.6% of post-session concentrations were less than 80 mg/L, and 38% of patients had at least one concentration outside the predefined target range.
CONCLUSIONS: MARS therapy was associated with a one-third reduction in total plasma piperacillin concentrations per session. These findings support systematic therapeutic drug monitoring and individualized antibiotic dose adjustment during MARS therapy.